 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The latest announcement is out from Chimerix (CMRX). Patrick Machado has announced his resignation from the Board of Directors of Chimerix, Inc., e...

Chimerix Board Changes: Machado Resigns, Kozin Appointed

Veteran Industry Executive Brings More Than 35 Years of Corporate Strategy ExperienceDURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose...

Chimerix Appoints Marc D. Kozin to Board of Directors

StockNews.com upgraded shares of Chimerix (NASDAQ:CMRX  Free Report) from a sell rating to a hold rating in a research report released on Monday.
Other research analysts also recently issued...

Chimerix (NASDAQ:CMRX) Raised to "Hold" at StockNews.com

Chimerix ( NASDAQ:CMRX ) Full Year 2023 Results Key Financial Results Net loss: US$82.1m (down by 148% from US$172.2m...

Chimerix Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Chimerix: Tackling A Strong Unmet Need With Promising Data...

Chimerix: Tackling A Strong Unmet Need With Promising Data

ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology $204...

Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Chimerix files $250M mixed securities shelf

DURHAM, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...

Chimerix to Present at TD Cowen 44th Annual Health Care Conference

DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...

Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Volume (M)	426,674.00
52-Wk High	$1.57
52-Wk Low	$0.88

CMRX Chimerix Inc

About

Feed

News

Sentiment

Earnings

Fundamentals